Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Large Growth in Short Interest

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 2,800 shares, an increase of 250.0% from the February 28th total of 800 shares. Based on an average daily volume of 531,600 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are short sold.

Daiichi Sankyo Trading Down 2.1 %

Shares of OTCMKTS DSNKY traded down $0.54 on Friday, reaching $24.49. 234,256 shares of the company traded hands, compared to its average volume of 245,356. The company has a current ratio of 2.77, a quick ratio of 2.11 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $46.73 billion and a PE ratio of 28.47. The company has a 50 day moving average of $24.92 and a 200 day moving average of $28.89. Daiichi Sankyo has a fifty-two week low of $22.47 and a fifty-two week high of $42.48.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Friday, January 31st. The company reported $0.22 earnings per share for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. On average, equities research analysts forecast that Daiichi Sankyo will post 0.73 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.